Table 1.
Patient characteristics.
| Variables | Control (n = 49) | i.p.-PTX (n = 43) | BSC (n = 9) | p-Value (Ctrl vs. i.p.-PTX) |
|---|---|---|---|---|
| Pre-treatment factors | ||||
| Gender, Male: Female, n (%) | 34 (69): 15 (31) | 16 (35): 28 (65) | 4 (44): 5 (56) | 0.001 |
| Age, median (range), years | 66 (41–85) | 69 (42–81) | 71 (65–75) | 0.222 |
| Performance status, 0:1:2, n (%) | 43 (88): 6 (12): 0 (0) | 35 (81): 8 (19): 0 (0) | 3 (33): 2 (22): 4 (44) | 0.397 |
| Charlson Comorbidity Index, 2:3:4:5:6, n (%) |
32(65): 32 (4): 13 (27): 1 (2): 1 (2) | 28 (65): 3 (7): 12 (28): 0 (0): 0 (0) |
7 (78): 2 (22): 0 (0): 0 (0): 0 (0) |
0.577 |
| Primary tumor site, Ph: Pbt, n (%) | 22 (45): 27 (55) | 13 (30): 30 (70) | 3 (33): 6 (67) | 0.147 |
| Radiological tumor size, median (range), mm | 41 (10–91) | 43 (15–105) | 50 (33–88) | 0.891 |
| NCCN resectability status of primary tumor, R:BR:UR, n (%) |
11 (23): 8 (16): 30 (61) | 10 (23): 5 (12): 28 (65) | 0 (0): 8 (89): 1 (11) | 0.809 |
| Peritoneal nodule, n (%) | 32 (65) | 27 (63) | 6 (67) | 0.802 |
| CA19-9, median (range), U/mL | 215 (1.9–18289) | 462 (1–8083) | 2430 (118–18977) | 0.153 |
| Systemic chemotherapy regimen, n | ||||
| GEM | 22 | NA | NA | |
| GEM + S-1 | 9 | 7 | NA | |
| S-1 | 2 | NA | NA | |
| GEM + nab-PTX | 10 | 17 | NA | |
| mFFX | 1 | NA | NA | |
| S-1 + PTX | NA | 19 | NA | |
| α+ RT | 5 | NA | NA | |
| Post-treatment factors | ||||
| Normalization of CA19-9, n (%) | 19 (38) | 18 (42) | NA | 0.763 |
| Duration of primary treatment, median (range), months | 6.8 (0.3–53.0) | 7.6 (0.3- 24.6) | NA | 0.583 |
| Response, CR: PR: SD: PD, n (%) | 1 (2): 8 (16): 33 (67): 7 (14) | 0 (0): 13 (30): 22 (51): 8 (19) | NA | 0.214 |
| Proportion of conversion surgery, n (%) | 2 (4) | 10 (23) | NA | 0.005 |
Ph, pancreas head; Pbt, pancreas body and tail; NCCN, National Comprehensive Cancer Network; R, resectable; BR, borderline resectable; UR, unresectable; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available; GEM, gemcitabine; nab-PTX, nab-paclitaxel; α, gemcitabine or S-1; RT, radiotherapy; mFFX, modified FOLFIRINOX; i.p.-PTX, intraperitoneal paclitaxel; Ctrl, control; BSC, best supportive care.